Tumor lysis, adverse events, and dose adjustments in 297 venetoclax treated CLL in routine clinical practice

PURPOSE: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AEs), and impact of dos...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Roeker, Lindsey E., Fox, Christopher P., Eyre, Toby A., Brander, Danielle M., Allan, John N., Schuster, Stephen J., Nabhan, Chadi, Hill, Brian T., Shah, Nirav N., Lansigan, Frederick, Yazdy, Maryam, Cheson, Bruce D., Lamanna, Nicole, Singavi, Arun K., Coombs, Catherine C., Barr, Paul M., Skarbnik, Alan P., Shadman, Mazyar, Ujjani, Chaitra S., Tuncer, Hande H., Winter, Allison M., Rhodes, Joanna, Dorsey, Colleen, Morse, Hannah, Kabel, Charlene, Pagel, John M., Williams, Annalynn M., Jacobs, Ryan, Goy, Andre, Muralikrishnan, Sivraj, Pearson, Laurie, Sitlinger, Andrea, Bailey, Neil, Schuh, Anna, Kirkwood, Amy A., Mato, Anthony R.
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020996/
https://ncbi.nlm.nih.gov/pubmed/31004001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0361
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker